OUR PLATFORM
GenomOncology's Precision Oncology Platform (POP) powers our end-to-end clinical informatics solutions for cancer. Our POP houses our extensive set of complex rules, annotations, and ontologies to create a flexible, cross-functional augmented intelligence stack that allows users to move, convert, and interpret complex data sets. Our comprehensive suite of APIs and toolset empowers researchers and clinicians to extend the POP's knowledge to maintain their own curated repositories and to integrate our solutions into their existing precision oncology workflows.
Our POP is at the heart of our augmented intelligence platform for precision medicine.
OUR EXTENDABLE MODEL
Curated Content
Directly access all biomarker-based clinical trials and therapies curated through our in-house curation team and partnerships with leading content institutions.
Variant Annotations
Our POP includes various annotation sets, including HGVS, COSMIC, gnomAD, ClinVar and more, which are kept up-to-date through our quarterly releases. We are also able to load and integrate your proprietary or licensed datasets.
Genomic Model
Our POP has the ability to parse complex mutations including protein expressions, chromosomal markers, and markers of genomic instability. Biomarkers are tied to higher level concepts, such as pathways or alteration groups for comprehensive matching.
Disease Ontology
Our up-to-date, expandable disease ontology includes a full NCI disease hierarchy and disease codes including SNOMED, OncoTree, and institutional codes. The ontology is used in our match algorithm so specific disease types qualify for more generic treatment inclusion rules.
Clinical Data
We built our POP to be able handle large amounts of clinical data so that a patient's medical history can be tracked and aggregated both for matching and for large scale analyses. Institutions can upload their own clinical data or use our tools to view publicly-available data such as GENIE or TCGA.
Molecular + Clinical Eligibility Criteria
We have curated molecular and clinical data so that our proprietary match algorithm can provide appropriate clinical trials, therapies, and prognosis matched to a patient's biomarkers, disease and prior therapies.
GERMLINE
SOMATIC
Our biomarker capabilities with the POP not only enables the analysis of complex somatic variants, but also germline variants in order to support every aspect of your genomic testing and analysis needs.
STANDARD
EXTENDABLE
Our POP can be used as a search engine to browse each of our knowledge sets. Users can also use our GO CLI tools and GO Connect to extract, transform, and load data into our POP so that their own curated content can be added to our database.
UI API
Interact with our POP through our pre-defined user interfaces (UI) or leverage our APIs for knowledge-driven matching, variant annotations, and more. Users can also use our command line interface to extract, transform, and load data into our POP models.
REQUEST
STORE
Our POP works"statelessly," enabling you to send requests to our APIs and get back a specific calculated output, or "statefully," enabling you to store, analyze, and track your clinical data.
SECURITY & INTEGRATION
Our POP can be utilized as the molecular plumbing that supports all of your precision oncology needs without the transfer of any Protected Health Information (PHI). We built a fully secure platform that is compliant with all HIPAA protections and can integrate with your existing security infrastructure.
OUR PLATFORM IN USE
BAYLOR
Baylor uses our POP to support their comprehensive tests covering a broad spectrum of germline and somatic genetic disorders. Their genetics team is able to annotate and curate massive biomarker sets at rapid speeds.
INDIANA UNIVERISTY
Indiana University has integrated our clinical trial matching APIs into their existing Precision Health UI that enables them to send biomarker and disease information to our POP and receive clinical trial recommendations in return.
GENOMICS ENGLAND
Genomic England is leveraging our POP as a key content driver to augment their 100,000 Genomes Project’s cancer program, with Vanderbilt University's My Cancer Genome content and the most relevant treatment information.